
S1169 Twelve-Month Interim Analysis of Efficacy and Safety of Givosiran, an Investigational RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open Label Extension
Author(s) -
Eliane Sardh,
Manisha Balwani,
David C. Rees,
Penelope E. Stein,
Ulrich Stölzel,
P. Aguilera Peiró,
D. Montgomery Bissell,
Herbert L. Bonkovsky,
Sioḃán Keel,
Charles J. Parker,
John D. Phillips,
Samuel M. Silver,
Jerzy Windyga,
Delia D’Avola,
Gayle Ross,
Peter Stewart,
Bruce Ritchie,
Pauline Harper,
JiaanDer Wang,
Janneke G. Langendonk,
Aneta Ivanova,
Yutaka Horie,
Karl E. Anderson,
Paolo Ventura,
Maria Domenica Cappellini,
Daphne Vassiliou,
Susana Monroy,
Petro E. Petrides,
Tomohide Adachi,
David J. Kuter,
Sushama Scalera,
Craig Penz,
Shangbin Liu,
John J. Ko,
Amy Simon,
Laurent Gouya
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000706724.29564.0b
Subject(s) - medicine , placebo , porphobilinogen , gastroenterology , clinical endpoint , clinical trial , pharmacology , porphyria , pathology , alternative medicine